Raloxifene Treatment Is Associated With Increased Serum Estradiol and Decreased Bone Remodeling in Healthy Middle‐Aged Men With Low Sex Hormone Levels

  title={Raloxifene Treatment Is Associated With Increased Serum Estradiol and Decreased Bone Remodeling in Healthy Middle‐Aged Men With Low Sex Hormone Levels},
  author={B Uebelhart and François R. Herrmann and Imre P{\'a}v{\'o} and Michael W. Draper and Ren{\'e} Rizzoli},
  journal={Journal of Bone and Mineral Research},
In healthy middle‐aged men, raloxifene treatment was associated with increased serum estradiol and decreased biochemical markers of bone turnover in subjects with estradiol levels below a threshold of 101.8 pM. 
Estrogen in men: effects on bone accrual, maintenance and prevention of bone loss
Clinical and experimental evidence that estrogens are essential for bone accrual in the growing skeleton, maintenance of bone mass and prevention of bone loss in men are summarized.
Effects of the SERM raloxifene on calcium and phosphate metabolism in healthy middle-aged men.
  • B. UebelhartF. HerrmannR. Rizzoli
  • Medicine, Biology
    Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases
  • 2009
Results are compatible with the hypothesis that raloxifene is associated with lower IGF-I and 1,25(OH)(2)D(3) levels, with consequently reduced intestinal calcium absorption capacity.
New Insights Into Androgen and Estrogen Receptor Regulation of the Male Skeleton
  • S. Khosla
  • Biology, Medicine
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 2015
There is now considerable evidence from observational and interventional studies that estrogen is the dominant regulator of bone metabolism in men, and a legitimate argument can be made that testosterone is largely a prohormone for the skeleton, with its effects on bone mediated principally via aromatization to estrogen.
The use of selective estrogen receptor modulators on bone health in men
The effects of SERMs on bone mineral density (BMD)/content (BMC), bone histomorphometry, bone turnover, bone strength and fracture risk have been summarized in this review.
Modulation of bone turnover in orchidectomized rats treated with raloxifene and risedronate
It is concluded that orchidectomy induced osteoporosis and increased bone turnover in male rats because of withdrawal of sex hormones.
Raloxifene preserves phenytoin and sodium valproate induced bone loss by modulating serum estradiol and TGF-β3 content in bone of female mice.


Effects of Raloxifene, a Selective Estrogen Receptor Modulator, on Bone Turnover Markers and Serum Sex Steroid and Lipid Levels in Elderly Men
Raloxifene has no significant effect on bone turnover markers or lipid levels in elderly men, but the association noted between baseline estradiol levels and the change in urine NTX excretion in the ralox ifene‐treated men suggests that a subset of men with low estradio levels may respond to ral oxifene or other SERMs, and further studies are needed.
Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency.
The sex steroids are critically important in helping to establish peak bone mass for both sexes and the more bone mass one gains in the formative years, the less likely it is that increased bone resorption and decreased bone formation will result in osteoporosis.
Raloxifene: Recent information on skeletal and non-skeletal effects
New information on the effects of raloxifene in breast cancer prevention, cardiovascular disease in high-risk women, and uterine disorders is reviewed.
A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women
Study results indicate that raloxifene may provide beneficial effects to bone and serum lipids in humans without uterine stimulatory effects.
Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen.
It is shown that age-related bone loss may be the result of E deficiency not just in postmenopausal women, but also in men, and bioavailable E levels decline significantly with age and are important predictors of BMD in men as well as women.
Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men.
It is concluded that in aging men, E is the dominant sex steroid regulating bone resorption, whereas both E and T are important in maintaining bone formation.
The effect of aromatase inhibition on sex steroids, gonadotropins, and markers of bone turnover in older men.
It is concluded that aromatase inhibition can reduce estrogen levels in older men, but this effect is limited, perhaps because of feedback stimulation of testosterone production, and that endogenous estrogen derived from aromatization of testosterone plays a role in bone metabolism of older men by limiting the rate of bone resorption.
Low levels of estradiol are associated with vertebral fractures in older men, but not women: the Rancho Bernardo Study.
The data suggest that estrogen plays a critical role in the skeletal health of older men and confirm other studies showing no association of postmenopausal endogenous estrogen levels with vertebral fractures in older women.
Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men.
The data indicate that estrogen plays a key role both in the acquisition of peak bone mass in young men and in bone loss in elderly men, and suggest that age-related decreases in bioavailable estradiol levels to below 40 pmol/liter may well be the major cause of bone lossIn elderly men.
Bioavailable estradiol may be an important determinant of osteoporosis in men: the MINOS study.
It is found in a cross-sectional analysis of a cohort of men that low levels of bio-17betaE(2) are associated with high bone turnover and low BMD, and low 17betaE (2) levels may be an important risk factor for osteoporosis in men.